40-year-old woman with calcifications detected on baseline screening mammography

 

40-year-old woman with calcifications detected on baseline screening mammography. (Left) Lateral and (right) craniocaudal magnification views show grouped pleomorphic calcifications in right breast (circles). Stereotactic-guided core-needle biopsy yielded radial scar without atypia. Subsequent surgical resection yielded radial scar (i.e., not upstaged).


March 15, 2024 — Screening-detected radial scars without atypia at core-needle biopsy (CNB) have a low upstaging rate to breast cancer of 1.6%, according to the American Journal of Roentgenology (AJR).

“Imaging surveillance rather than surgery is a reasonable approach for radial scars without atypia, particularly for those presenting as calcifications,” wrote coauthor Manisha Bahl, MD, MPH, from Massachusetts General Hospital in Boston.

First delivered as an oral presentation during the 2023 American Roentgen Ray Society (ARRS) Meeting in Honolulu, HI, Dr. Bahl and AJR coauthor Claire Crowley, MB, BCh, BAO, MSc, studied patients who underwent CNB showing radial scar after screening digital breast tomosynthesis (DBT) and digital mammography (DM) (January 1, 2013–December 31, 2020). Patients without surgical excision or at least 2 years of imaging follow-up after CNB were excluded. Rates of upstaging to breast cancer [ductal carcinoma in situ (DCIS) or invasive disease] were compared between radial scars with and without atypia at CNB. Associations of upstaging with patient, imaging, and pathologic variables were explored via statistical testing

Ultimately, among radial scars detected by screening DBT, the upstaging rate to breast cancer for those without atypia was 1.6% (2/129) and for those with atypia was 20.0% (6/30) (p<.001). Of 34 radial scars presenting as calcifications, none was upstaged to cancer.

Bahl and Crowley’s AJR accepted manuscript “also identified features other than atypia that are associated with upstaging risk, including age, a prior diagnosis of breast cancer, and a family history of breast cancer.”

For more information: www.arrs.org


Related Content

News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
Subscribe Now